Shenzhen Genoimmune Medical Institute is founded by Shenzhen Government in 2015 and come into construction in 2016.The key function and goal of this institute are to provide contracted research & technical services for individually cell-based immunotherapy.  
 
The research team consists of many experienced scientists with expertise of clinical & translational research as headed by Dr. Lung-Ji Chang.  The advanced lentiviral vector technologies associated with CAR-T and Gene therapy will be our core competence to develop various therapeutic solutions for cancers and other genetic diseases. 

We are able to develop the 4th generation CAR-T therapeutic products with safety design to control the viability of target-specific T-cells, which is clinically proven to be the best solution to deal with the adverse effect (CRS) during CAR-T treatment; thus it is also the best therapeutic strategy for clinical applications.